Search PubMed⌕ Search

Biomedical subjects

N Masaki

Publications and source records attributed to N Masaki.

At least 91 records · Page 5Linked to original sources
PubMed1988

[Analysis of non-Hodgkin's lymphomas of 210 patients with nodular and favorable histologies--report of the Japanese Lymphoma Radiation Therapy Study Group].

Between 1972 and 1985, 210 patients with nodular poorly differentiated lymphocytic (NPDL), nodular mixed lymphocytic and histiocytic (NM), nodular histiocytic (NH), or diffuse well differentiated lymphocytic (DWDL) lymphoma according to Rappaport classification were treated among the 7 hospitals belonging to JLRTG (Japanese Lymphoma Radiation Therapy Study Group). Age greater than 50 years adversely affected overall survival. But no obvious survival differences were seen by sex and the primary site. Patients with NH had a significantly poorer survival (P less than 0.01), while there were no differences among the other histologic groups. Aggressive combination chemotherapy is advisable for patients with stages II, II and IV NH. But radiotherapy along may be treatment choice for patients with stage I NH. Because among stage I, over all survival and relapse-free survival of patients with NH were similar to those with the other histologic types. Five-year and 10-year relapse-free survival of stage I patients with the other 3 histologic types by radiotherapy alone were 85% and 67%, respectively. Those of stage II patients were both 58%. These data suggest cure of more than 50% of stages I and II patients with favorable lymphoma by radiotherapy alone.

Adolescent↗
PubMed1988

[Results of the treatment of localized non-Hodgkin's lymphoma originated in the thyroid gland].

A total of 38 cases of localized non-Hodgkin's lymphoma originated in the thyroid gland were treated at the Department of Radiology, Osaka University Hospital from 1967 through 1986. There were 18 males and 20 females, and age ranged from 15 to 78, averaging 58 years. Fifteen cases were classified as clinical stage I and 23 as stage II. All cases were histologically confirmed, 15 by total or partial resection and 23 by open biopsy, and diffuse histiocytic was most common (18 cases) and diffuse lymphocytic, poorly differentiated was the next (15) after Rappaport classification. Those were further classified into intermediate grade after Working Formulation in 76% of the cases. In all patients local were controlled by radiotherapy by 40-50 Gy in 5 to 6 weeks. Local lesion was assessed as uncontrolled in only one patient at dose of 33 Gy, who was immunoblastic in histology, and with infiltration to local skin. No local relapse occurred after treatment. The relapse outside the treatment field was seen in 9 patients, all of which occurred in the abdomen. Overall 5 year survival rate and relapse-free rate were 72% and 64%, respectively. Five-year survival rate for Stages I and II were 84% and 63%, respectively (Z = 0.7445, N.S.). Five-year survival rate for thyroidal swelling with longer diameter less than 11 cm is 83%, whereas that with more than 12 cm is 61% (z = 0.7525, N.S.).

Abdominal Neoplasms↗
PubMed1988

[The role of radiation therapy in the management of the Hodgkin's disease].

Radiation therapy has curative potential for patients with stage I-II disease, and five-year relapse-free survival rate in excess of 80% can be expected. Despite an advantage of chemotherapy combined with radiation therapy in improving relapse-free survival, no significant advantage has yet been demonstrated in allover survival. Patients with stage IIIA1 may also be treated radiation therapy alone with results of five-year survival rate of 53-60%. However, patients with stage IIIA2 should be treated with chemotherapy with or without radiation therapy combined.

Age Factors↗
PubMed1988

[Late complications of radiation therapy in patients with malignant lymphoma].

The improvement on the treatment of malignant lymphoma have led to prolonged survival for many patients. However, they are at risk of late complications of the disease and treatment. Impaired function due to radiation-induced injury of normal tissues, such as cardiac, pulmonary, or thyroid dysfunction, becoming manifest at few months to years after treatment. Fortunately, only a small portion of these are major complications, causing severe, or permanent disability. The frequency of secondary leukemia (AML) occurring in patients treated for malignant lymphoma is highest in those patients receiving many courses of combination chemotherapy and is low in those receiving radiation therapy alone.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1988

[The role of radiation therapy in the management of non-Hodgkin's lymphoma].

For patients with stage I-II malignant lymphoma with low-grade malignancy, five-year survival rates after radiation therapy are 75-100%. For patients with intermediate malignancy, five-year survival rates after radiation therapy alone are 70-100% for patients with pathological stage I-II and 45-75% for clinical stage I-II. Radiation dose to the tumor at least 40 Gy was required to produce consistent local control. Initial use of chemotherapy with radiation therapy is indicated to improve relapse-free survival rate for patients with clinical stage I-II, as well as pathological stage I-II.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1988

[Results of radiation therapy of stage I-II non-Hodgkin's lymphoma localized in the head and neck--a report of the Japanese Lymphoma Radiation Therapy Study Group].

A retrospective analysis of 1514 patients with non-Hodgkin's lymphoma treated between 1972 and 1985 was performed. Of these cases, 114 with histology of low-grade malignancy and 750 with intermediate malignancy were localized in the head and neck. All patients received definitive course of radiation therapy, including 390 cases with adjuvant chemotherapy. For cases with low-grade malignancy, all cases were locally controlled and five-year relapse free survival rates were 85% in stage I, and 75% in stage II. For cases with intermediate malignancy, local control rates were 97% in stage I, and 87% in stage II. Five-year survival rates were 67% in stage I and 50% in stage II. There were no benefit on survival rates from adjuvant use of chemotherapy with radiation therapy as compared to radiation therapy alone.

Head and Neck Neoplasms↗
PubMed1988

[Results of radiation therapy of stage I-II non-Hodgkin's lymphoma localized in the head and neck: Osaka University Hospital experience].

A retrospective analysis of 251 patients (stage I: 125; stage II: 126) with non-Hodgkin's lymphoma localized in the head and neck and treated between 1971 and 1985 was performed. Of these, 28 patients (11%) had histology of low-grade malignancy, and 218 (87%) had intermediate malignancy. Waldeyer's ring was the most frequent site of involvements (114 cases), extranodal site (91), and cervical lymph node(s) (46) in the order. Treatment consisted of radiation therapy alone in 173 patients and 78 patients were treated with chemotherapy combined. Local control rates by radiation therapy was 95%. Five-year survival and relapse-free survival rates were 72% and 61%, respectively, in stage I, and 63% and 54%, respectively, in stage II. A brief chemotherapy for 2 cycles followed by local-regional radiation therapy appeared better survival as compared to initial radiation therapy alone.

Adolescent↗
PubMed1988

[Results of radiation therapy of stage II non-Hodgkin's lymphoma of the Waldeyer's ring: a report of the Japanese Lymphoma Radiation Therapy Study Group].

A retrospective analysis of 245 patients with stage II non-Hodgkin's lymphoma of the Waldeyer's ring treated between 1972 and 1985 was performed. Treatment consisted of radiation therapy alone in 96 patients and 149 patients were treated with chemotherapy combined. Five-year survival and relapse-free survival rates were 57% and 50%, respectively. For cases with DH, they were 64% and 55% respectively, and for DLPD 31% and 27%, respectively. Of the cases with relapse, 21% were seen in stomach or intestine. There were no difference on survival rates between radiation therapy alone and chemotherapy combined with radiation therapy.

Combined Modality Therapy↗
PubMed1988

[Results of radiation therapy in extranodal non-Hodgkin's lymphoma of the head and neck--a study of the Japan Lymphoma Radiation Therapy Study Group].

Extranodal non-Hodgkin's lymphoma (NHL) in the head and neck except Waldeyer's ring treated with radiation were analyzed. No definite difference was observed both in actuarial and relapse-free five-year survival rate between stage I and II. There was a high survival rate with orbital NHL in which most of the patients occupied with favorable histology. Prognosis of the disease was highly influenced by the histologic subtype; five-year survival was 91.4% in DWDL, 77.2% in the DM, 52.0% in DPDL and 51.7% in DH. Application of histologic classification with the Working Formulation was also recommended. There was a high incidence of extranodal relapses to bone and/or soft tissue from the lesions with nasal cavity, paranasal sinus and oral cavity.

Adolescent↗
PubMed1988

[Results of radiation therapy of stage I and II nodal non-Hodgkin's lymphoma originated in the cervical lymph nodes--a study of the Japan Lymphoma Radiation Therapy Study Group].

During the years 1972-81, 118 patients with stage I (78 cases) and II (40) nodal non-Hodgkin's lymphoma originated in the neck were treated with radiation. 5 year survival rates were 74% for stage I and 40% for stage II. Favorable histology group showed better prognosis than unfavorable one. Among stage I patients with unfavorable histology group, prognostic factors were studied and tumor size larger than 4 cm is found to be a sole prognostic factor.

Adolescent↗
PubMed1988

[Results of the treatment of malignant lymphoma of the brain--a report of Japan Lymphoma Radiation Therapy Group (JLRTG)].

Retrospective analysis of patients with malignant lymphoma of the brain was carried out. All cases were mainly treated with radiation therapy. Overall survival was 44% and 37% at two and five year. Survival was statistically better for patients with diffuse medium-sized cell or diffuse mixed type compared with diffuse large cell type by the LSG classification, for the age group less than 50 years compared with greater than or equal to 50 years, and for the group with Karnofsky Index greater than or equal to 50% compared with less than or equal to 40%. In 11 of 15 patients the first recurrent site was the central nervous system.

Adolescent↗
PubMed1988

[Recurrence of non-Hodgkin's lymphoma: local control failures and regional recurrences].

From 1972 to 1982, 563 patients with Stage I and II non-Hodgkin's lymphoma received radiation therapy in the department of radiology which belongs to the JLRTS group. Local control failures were seen in only 5 cases (0.9%). The regional recurrences were found in 30 cases (5%). 17 of recurrences occurred during the first 5 years. 17 cases had remissions again, and 5 cases had 5 year survivals.

Combined Modality Therapy↗
PubMed1988

[Recurrence of non-Hodgkin's lymphoma: late recurrences].

563 patients with Stage I and II non-Hodgkin's lymphoma were treated by radiotherapy. 34 recurrences that occurred after 3 years from initial treatment were seen in those patients. 15 (44%) of 34 recurrences occurred after 5 years. 20 patients (59%) had remission by re-treatment, and 13 (38%) survived more than 2 years. 20 (59%) of recurrences were seen on head and neck lesions and superficial lymph nodes.

Adult↗
PubMed1988

[Results of the radiotherapy of Hodgkin's disease (a JLRTG report). Japan Lymphoma Radiation Therapy Group].

A total of 234 patients of Hodgkin's disease treated at 7 institutions from 1972 through 1985 were analyzed. Male to female ratio was 157: 77, mean age was 39.8 years, and overall 5- and 10-year survival were 67% and 56%, respectively. Of 126 patients treated by radiotherapy with more than 36 Gy, alone or preceded to other treatments, 5- and 10-year survival rates were 84% and 80% for Stage I (43 patients), 79% and 69% for Stage II (71 pts.), and 52% and none for Stage III (12 pts.), respectively. Survival rate was better for LP, NS and MC histologies as compared to LD, better for patients without constitutional symptoms, as compared to patients with B, and better for patients with ages younger than 59 years as compared to those with ages over 60 years. Relapse was observed in 57 out of 126 patients. Relapse within the irradiation field was observed in only 4, and nodal areas outside the field, especially of abdomen (1/3), were the most common sites. Half of the relapses occurred within 20 months, and 80%, 40 months. Five-year survival of patients after relapse to lower torso lymph nodes (19 patients) was 37%, which was worse than patients after relapse to upper torso lymph nodes (15 patients: 63%) (z = 1.507, N.S.).

Adolescent↗
PubMed1988

[Results of the radiotherapy of Hodgkin's disease (Analysis of cases at Osaka University Hospital)].

A total of 32 patients of Hodgkin's disease treated mainly by radiotherapy at the Department of Radiology, Osaka University Hospital from 1971 through 1985 were analyzed. Five- and ten-year survival rates for all patients were 91%, 78%; Clinical Stage I (15 patients): 93%, 83%; Stage II (8 pts.): 100%, 100%; Stage III (9 pts.): 78%, 52%, respectively, and 5- and 10-year relapse-free rates for all patients: 72%, 62%; St. I 87%, 76%; St. II: 63%, 63%; St. III: 56%, 42%, respectively. Patients with tumor originated in the upper neck consisted of 7 patients (47%) in Stage I and no relapse was observed outside the irradiated field. However, 2 recurrences (1 within RT field, and another Stage III at margin of the field) were observed around the upper neck in patients treated with only the mantle field encompassing the upper neck area. Treatment portal should be considered to cover Waldeyer's ring and skull base with lateral portals.

Adolescent↗
PubMed1988

[A study on the correlation of histopathological findings with prognostic factors in maxillary antrum carcinoma].

Radiotherapy is usually employed as a part of a multidisciplinary treatment for squamous cell carcinoma of the maxillary antrum. In general, the clinical stage classification relates well with the prognosis. Sometimes, however, even early cases may have a poor prognosis if some other prognostic factors also are related. According to the histopathological findings of biopsy specimens of 74 patients, a grading on malignancy is discussed. Three different morphological parameters have been evaluated with respect to the tumor cell population in terms of the four-point scale. This has permitted a grading with total points ranging from 3-12. The correlation between the degree of histopathological malignancy and neck node metastasis has been found to be remarkable.

Carcinoma, Squamous Cell↗
PubMed1987

Role of cell-surface modulator of DNA synthesis in liver regeneration.

A cell-surface modulator of DNA synthesis by cultured rat hepatocytes was studied in relation to the liver regeneration process. When rat hepatocytes isolated 24 h after partial hepatectomy were cultured, the first burst of DNA synthesis peaked at 5-8 h and declined until 24 h, followed by the second burst. Rat liver plasma membranes added 2 h after plating inhibited only the second burst, while in the case of the normal hepatocytes where the DNA synthesis began to increase after 5 h, this inhibition was observed at 16 h but not at 8 h. The inhibition did not differ when the membranes obtained from regenerating livers 12 h after partial hepatectomy were used. Epidermal growth factor binding to the cultured hepatocytes was not hindered by the membranes. These results suggest that the modulator inhibits hepatocyte proliferation at the early G1-phase of the cell cycle and that its action might be controlled by other factors in the process of liver regeneration.

Animals↗